Trial Profile
Effect of sofosbuvir and daclatasvir plus ribavirin on liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients: An observational study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics; Therapeutic Use
- 26 Jul 2018 New trial record
- 01 Dec 2017 According to results published in the European Journal of Gastroenterology and Hepatology, recruitment completed in October 2016.